Published in the top chemistry journal! Maikokang Biological Adjuvant Team Collaborates to Publish New Adjuvant System Applied to Tumor Vaccines

Recently, the cooperative research paper "Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjustments of 3D-MPL and QS-21", developed by Chengdu Maikekang Biotechnology Co., Ltd. (hereinafter referred to as "Maikekang Biotechnology"), based on the application of new compound adjuvants in tumor immunity, was published online in the internationally renowned journal "Angelwandte Chemie International Edition" (impact factor 16.1). Shanghai Anyikang Biotechnology Co., Ltd., a wholly-owned subsidiary of Maikekang Biotechnology, and the Chinese Academy of Sciences Shanghai Institute of Materia Medica and Hainan University were the joint communication units of the article.

（ALL URL：https://onlinelibrary.wiley.com/doi/10.1002/anie.202418948）

Compared to traditional aluminum adjuvants, the new adjuvant can significantly enhance immune efficacy to enhance the protective effect of vaccines. In recent years, adjuvants have also been widely used in tumor immunity and have become one of the core elements in vaccine development. To promote the in-depth research and development of adjuvants, it is necessary to develop efficient and large-scale preparation methods to obtain high-quality and diverse adjuvant molecules, thereby promoting the development of new vaccines.

The new adjuvant system developed in collaboration with Maikokang Biotechnology can enhance the anti-tumor immunity of Globo H sugar vaccine, laying a solid foundation for the development of corresponding therapeutic vaccines. Globo H is a carbohydrate antigen that is overexpressed in various malignant tumors and has the potential to serve as a therapeutic tumor vaccine target. Despite the existence of various tumor immune designs based on Globo H, efficiently synthesizing Globo H hexose antigen and combining it with adjuvants to enhance immune response remains a challenge. This study developed an effective chemical enzymatic synthesis method that combines chemical synthesis with enzymatic glycosylation to obtain high-purity Globo H hexose antigen, which efficiently binds to carrier proteins and has higher stereoconstruction efficiency and large-scale production potential. In addition to innovative antigen synthesis, the study also delved into the preparation, selection, and combination of relevant adjuvants.

In addition to the 3D-MPL, QS21, and KRN7000 adjuvants demonstrated in this study, Maikokang Biotechnology has independently developed over 20 types of adjuvant raw materials, created three mature delivery systems, developed more than 10 composite formulas, and formed a vertical industry chain from adjuvant raw material research and development, production to adjuvant formula development and application. Based on the company's innovative adjuvant platform, a series of preventive vaccines and tumor treatment vaccines have been developed. Maikokang Biotechnology will continue to promote the independent research and development of new adjuvants, solve the problem of adjuvant source, develop safer and more efficient adjuvant systems, and promote clinical application and development.